Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
June 20, 2024 11:37 ET
|
Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency
May 31, 2024 10:03 ET
|
Zealand Pharma
Press release – No. 6 / 2024 Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency ...
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide
May 23, 2024 14:45 ET
|
Zealand Pharma
Company announcement – No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean...
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
January 08, 2024 15:45 ET
|
Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th
January 02, 2024 02:00 ET
|
Zealand Pharma
Press Release – No. 1 / 2024 Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4th Copenhagen, Denmark, January 2, 2024 – Zealand...
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
December 04, 2023 02:30 ET
|
Zealand Pharma
Press release – No. 16 / 2023 Zealand Pharma to highlight obesity pipeline at R&D Event on December 5 Event to be hosted by company management and feature key external scientific and...
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
November 30, 2023 02:00 ET
|
Zealand Pharma
Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no....
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
November 09, 2023 01:00 ET
|
Zealand Pharma
Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for...
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023
November 07, 2023 04:00 ET
|
Zealand Pharma
Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL)...
Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results
November 03, 2023 12:00 ET
|
Zealand Pharma
Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand...